Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)
| Autor: | Elena Brioschi, G. Rossoni, Maria Grazia Viganò, Scialini Colombi, Giulia Salini, Claudio Bordignon, Giovanna Petrella, Vanesa Gregorc, Luca Gianni, Giovanni Citterio, Alessandra Bulotta, Veronica Savia, Monika Ducceschi, Antonio Lambiase |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty business.industry Pleural mesothelioma Placebo Surgery Double blind 03 medical and health sciences Regimen 030104 developmental biology 0302 clinical medicine Pemetrexed Oncology NGR-hTNF 030220 oncology & carcinogenesis Internal medicine medicine Previously treated business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:e20077-e20077 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e20077 |
| Popis: | e20077Background: In the NGR015 trial, patients failing a pemetrexed-based regimen were randomly assigned to weekly NGR-hTNF (N; n = 200) or placebo (P; n = 200), both given with BIC that included ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|